Panacea Biotec announces inclusion of EmulsiPan into prestigious CEPI Adjuvant Library
Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects.
EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8C and maintains stability for over 2-years under recommended conditions.
On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
03-06-2025
- Business Standard
Panacea Biotec announces inclusion of EmulsiPan into prestigious CEPI Adjuvant Library
Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects. EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8C and maintains stability for over 2-years under recommended conditions. On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.
&w=3840&q=100)
Business Standard
24-04-2025
- Business Standard
Panacea Biotec shares locked in 5% upper circuit; here's what to know
Shares of Panacea Biotec surged to hit a 5 per cent circuit on Thursday's session after it received an additional order from the UNICEF for the supply of 40 million doses of its bivalent oral polio vaccine worth $5.20 million (₹44 crore). The pharmaceutical company's stock rose as much as 5 per cent during the day to hit an upper circuit of ₹538.55 per share. The stock trades near its all-time high of ₹549 per share, which it hit on April 21 this year. The company's shares are up 3 per cent this week and have recovered over 85 per cent from their lows of ₹290, which it hit in late February. The stock has risen 28 per cent this year, compared to a 2.6 per cent advance in the benchmark Nifty50. The company has a total market capitalisation of ₹3,300.8 crore, according to BSE data. In an exchange filing on Wednesday, it said that the company received an additional award from United Nations Children's Fund (UNICEF) for the supply of 40 million doses of its bivalent oral polio vaccine, valued at approximately US$5.20 million (around Rs 44 crore), for delivery in the third quarter of calendar year 2025. This comes after the company has already received orders from UNICEF for the supply of 115 million doses of its bivalent oral polio vaccine worth $14.95 million (~Rs.127 Crore) in this calendar year. About Panacea Biotec Panacea Biotec is an Indian biotechnology and pharmaceutical company specialising in the research, development, and manufacturing of vaccines, biologics, and pharmaceutical formulations. Established in 1984, the company is known for its innovative healthcare solutions, particularly in the areas of immunisation and life-saving therapeutics. Panacea Biotec has developed vaccines for diseases including polio, tetanus, and hepatitis, and collaborates with global organisations such as the WHO, UNICEF, and Gavi to distribute its vaccines worldwide. In addition to vaccines, its pharmaceutical portfolio covers therapies for oncology, organ transplantation, diabetes, and cardiovascular conditions. With a strong focus on research and cutting-edge technology, Panacea Biotec aims to address critical healthcare needs globally.
Hans India
23-04-2025
- Hans India
SK bioscience wins patent case against Moderna in South Korea
Seoul: SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a patent invalidation case against Moderna, the global developer of the messenger-RNA (mRNA) COVID-19 vaccine. SK bioscience filed a nullity suit in 2023 challenging Moderna's patent on modified nucleosides, nucleotides and nucleic acids, as well as their uses, the company said in a press release. Moderna's patent is the only registered patent in South Korea related to mRNA manufacturing technology, reports Yonhap news agency. SK bioscience had argued the patent "unfairly granted priority rights, which hindered the development of mRNA technology." The disputed patent was considered critical in mRNA manufacturing and was relevant to SK bioscience's own work, including its development of an mRNA-based Japanese encephalitis vaccine candidate, GBP560, the release said. SK bioscience has been developing this vaccine in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), a non-governmental organization founded by American billionaire Bill Gates. CEPI has provided funding of US$357 million over the past few years to South Korea's private and academic partners, including SK bioscience. "If developed, SK bioscience's mRNA vaccines could be exported to developing countries in Africa, the Middle East, Latin America and Southeast Asia, regions where Moderna has not yet registered patents for its mRNA vaccines," a company spokesperson said. The Intellectual Property Trial and Appeal Board ruled last month in favour of SK bioscience, a decision the company said will accelerate its efforts in the global race for mRNA vaccine technology. Moderna did not appeal the ruling within the legal timeframe. The global mRNA therapeutics market is expected to exceed 84 trillion won ($58.9 billion) by 2033, according to global market research firm Nova One Advisor. SK bioscience aims to establish an mRNA vaccine platform that addresses not only pandemics but also a broader range of infectious diseases.
